Tag: copies

NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Pelican Acquisition II Corporation (NASDAQ: PLCIU) (the “Company”), a Cayman Islands exempted company, announced that it priced its initial public offering of 7,500,000 units at $10.00 per unit on July 23, 2026. The units will be listed on the Nasdaq Capital Market (“NASDAQ”) and are expected to trade under the ticker symbol “PLCIU” beginning on July 24, 2026. Each unit consists of one ordinary share of the Company and one right, with each right entitling the holder thereof to receive one-tenth (1/10) of one ordinary share upon the consummation of an initial business combination.  

Limited Notice to Proceed authorizes approximately $6 million for procurement of long-lead equipment for Kalaeloa desalination facility

Boise, Idaho, July 06, 2026 (GLOBE NEWSWIRE) -- Idaho Copper Corporation (“Idaho Copper” and the “Company”) (NYSE American: COPR, COPR WS), a critical minerals developer advancing the flagship CuMo copper-molybdenum-silver project in Idaho, today announced the closing of its underwritten public offering of shares of its common stock and warrants at a public offering price of $4.85 per share and accompanying warrant for gross proceeds of approximately $18,000,000, before deducting underwriting discounts and offering expenses. In addition, Idaho Copper has granted the underwriters a 45-day option to purchase up to an additional 556,800 shares of common stock and/or warrants to cover over-allotments at the public offering price, if any. The offering also included the purchase by the underwriters of 556,800 warrants in connection with the partial exercise by the underwriters of their over-allotment option.

LIKMEZ® (ATI-1501) commercial momentum building in U.S. market

US$40 million NIAID award supporting VXV-01 advancement through Phase 1

Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination

BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY^®▼(nipocalimab) throughout clinically relevant points in the generalised myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChR^a or anti-MuSK^b antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common.^1,2 Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in the use of nipocalimab during pregnancy.^3,4